357 related articles for article (PubMed ID: 9026938)
1. [The prognostic significance of the beta 2-microglobulin level of the blood serum in multiple myeloma patients].
Lubo-Lesnichenko IF; Bessmel'tsev SS; Abdulkadyrov KM; Blinov MN; Stel'mashenko LV
Ter Arkh; 1996; 68(10):28-31. PubMed ID: 9026938
[TBL] [Abstract][Full Text] [Related]
2. [Prognostic importance of beta-2-microglobulin in multiple myeloma].
Avilés A; Zepeda G; Guzmán R; Talavera A; García EL; Díaz-Maqueo JC
Rev Invest Clin; 1992; 44(2):215-20. PubMed ID: 1439309
[TBL] [Abstract][Full Text] [Related]
3. [The significance of lactate dehydrogenase and beta 2-microglobulin levels for the assessment of the prognosis and choice of therapy in multiple myeloma].
Iakovleva SV; Andreeva NE; Izgorodin AS
Ter Arkh; 1995; 67(7):35-9. PubMed ID: 7482303
[TBL] [Abstract][Full Text] [Related]
4. [Clinical usefulness of serum beta2-microglobulin determination in patients with multiple myeloma].
Kraj M; Maj S; Pogłód R; Rostkowska J
Acta Haematol Pol; 1989; 20(2):140-51. PubMed ID: 2700533
[TBL] [Abstract][Full Text] [Related]
5. [Prognostic significance of beta-2-microglobulin in multiple myeloma].
Podol'tseva EI; Morozova EV; Almazov VA
Vopr Onkol; 1996; 42(4):32-5. PubMed ID: 8928455
[TBL] [Abstract][Full Text] [Related]
6. Stratification of multiple myeloma according to serum beta 2-microglobulin and serum albumin levels.
Scudla V; Budíková M; Fischerová E; Zadrazil J; Indrák K
Acta Univ Palacki Olomuc Fac Med; 1991; 130():201-12. PubMed ID: 1838869
[TBL] [Abstract][Full Text] [Related]
7. Staging multiple myeloma patients with active disease using serum levels of beta2m-free HLA class I heavy chain together with IgM or platelet count.
Perosa F; Minoia C; Favoino E; Prete M; Dammacco F
Blood Cells Mol Dis; 2009; 42(1):71-6. PubMed ID: 18996035
[TBL] [Abstract][Full Text] [Related]
8. Serum syndecan-1, basic fibroblast growth factor and osteoprotegerin in myeloma patients at diagnosis and during the course of the disease.
Kyrtsonis MC; Vassilakopoulos TP; Siakantaris MP; Kokoris SI; Gribabis DA; Dimopoulou MN; Angelopoulou MK; Pangalis GA
Eur J Haematol; 2004 Apr; 72(4):252-8. PubMed ID: 15089762
[TBL] [Abstract][Full Text] [Related]
9. [A study of the significance of serum beta 2-microglobulin levels in patients with multiple myeloma--analyzes as a marker of renal dysfunction and as a marker of tumor cell mass].
Nishinarita S; Shimada H; Suzuki R; Kishigami Y; Sawada U; Horie T
Rinsho Ketsueki; 1996 Mar; 37(3):201-7. PubMed ID: 8727343
[TBL] [Abstract][Full Text] [Related]
10. [Serum beta 2-microglobulin in multiple myeloma. I. Relation to selected indicators, clinical stage and disease prognosis].
Scudla V; Budíková M; Fischerová E; Raska I; Vavrdová V
Vnitr Lek; 1991 Apr; 37(4):342-51. PubMed ID: 2053304
[TBL] [Abstract][Full Text] [Related]
11. Prognostic factors and staging systems of multiple myeloma:
Tao ZF; Fu WJ; Yuan ZG; Wang DX; Chen YB; Hou J
Chin Med J (Engl); 2007 Oct; 120(19):1655-8. PubMed ID: 17935664
[TBL] [Abstract][Full Text] [Related]
12. International prognostic index (IPI)--a critical comparison with five multiple myeloma staging systems in the group of 270 patients treated by conventional chemotherapy.
Scudla V; Zemanova M; Minarik J; Bacovsky J; Ordeltova M; Indrak K; Budikova M; Dusek L; Farbiakova V
Neoplasma; 2006; 53(4):277-84. PubMed ID: 16830053
[TBL] [Abstract][Full Text] [Related]
13. A review of the cytokine network in multiple myeloma: diagnostic, prognostic, and therapeutic implications.
Lauta VM
Cancer; 2003 May; 97(10):2440-52. PubMed ID: 12733143
[TBL] [Abstract][Full Text] [Related]
14. [Prognostic value of serum beta2-microglobulin in multiple myeloma].
Bettini R; Redaelli S; Maino C; Bertuol S; Costantini C; Lazzarini A; Brivio L; Gorini M
Recenti Prog Med; 2005 Feb; 96(2):81-6. PubMed ID: 15844767
[TBL] [Abstract][Full Text] [Related]
15. Prognosis of asymptomatic multiple myeloma.
Alexanian R; Barlogie B; Dixon D
Arch Intern Med; 1988 Sep; 148(9):1963-5. PubMed ID: 2458080
[TBL] [Abstract][Full Text] [Related]
16. [Prognostic analysis and assessment on the clinical staging systems of multiple myeloma--a report of 206 cases].
Tao ZF; Fu WJ; Chen YB; Yuan ZG; Wang DX; Hou J
Ai Zheng; 2006 Apr; 25(4):461-4. PubMed ID: 16613681
[TBL] [Abstract][Full Text] [Related]
17. Total soluble HLA class I and soluble HLA-G in multiple myeloma and monoclonal gammopathy of undetermined significance.
Leleu X; Le Friec G; Facon T; Amiot L; Fauchet R; Hennache B; Coiteux V; Yakoub-Agha I; Dubucquoi S; Avet-Loiseau H; Mathiot C; Bataille R; Mary JY;
Clin Cancer Res; 2005 Oct; 11(20):7297-303. PubMed ID: 16243800
[TBL] [Abstract][Full Text] [Related]
18. Circulating angiogenic cytokines in multiple myeloma and related disorders.
Urba ska-Rys H; Wierzbowska A; Robak T
Eur Cytokine Netw; 2003; 14(1):40-51. PubMed ID: 12799213
[TBL] [Abstract][Full Text] [Related]
19. Clinical significance of correction of serum beta 2-microglobulin levels for serum creatinine in multiple myeloma.
Scudla V; Vavrdová V; Budíková M; Indrák K
Acta Univ Palacki Olomuc Fac Med; 1991; 131():257-64. PubMed ID: 1840347
[TBL] [Abstract][Full Text] [Related]
20. [Serum beta-2-microglobulin in multiple myeloma. Practical value].
Bataille R; Magub M; Sany J; Donadio D; Izarn P; Grenier J; Suquet P
Rev Rhum Mal Osteoartic; 1981 Mar; 48(3):235-40. PubMed ID: 6164091
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]